Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
By Marcus Bantscheff, D. Eberhard, Yann Abraham, Sonja Bastuck, Markus Boesche, S. Hobson, Toby Mathieson, Jessica Perrin, M. Raida, Christina E. Rau and 11 more. Nature Biotechnology, 2007
1,038 citations recorded by the source corpus.
Subfields: Hematology, Immunology, Rheumatology
View Paper: https://www.semanticscholar.org/paper/a8bdfd5a77f29d01e1614e58c99d350f3f112475
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Chunaram Choudhary
- Matthias Mann
- John R. Yates III
- Florian Gnad
- Jesper V. Olsen
- C. Ruse
- Mikhail M. Savitski
- A. Nakorchevsky
Citations in the corpus
- Decoding signalling networks by mass spectrometry-based proteomics (2010, methodology): “Quantitative MS combined with global phosphoproteomics is an attractive method for identifying targets of such inhibitors and for assessing their specificit”
- Dynamic Reprogramming of the Kinome In Response to Targeted MEK Inhibition In Triple Negative Breast Cancer (2012, neutral): “Kinase capture is reproducible and is a function of kinase expression, the affinity of kinases for the immobilized inhibitors, and the activation state of the kinase (Bantscheff et al., 2007).”
- Tracking cancer drugs in living cells by thermal profiling of the proteome (2014, methodology): “Competition binding assays were performed as described previously by using a modified bead matrix (5, 22).”
- Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes (2011, background): “Recent advances in chemoproteomics enabled binding studies of small-molecule enzyme inhibitors to endogenous proteins in cells and tissue”
- Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. (2008, background): “Moreover, immobilized kinase inhibitors with distinct kinase-binding properties can be combined for increased coverage of the expressed kinome in highly enriched cellular subfractions (Bantscheff et al., 2007; Wissing et al., 2007).”
- Proteomics by mass spectrometry: approaches, advances, and applications. (2009, methodology): “This approach combined with iTRAQ and MS revealed new drug targets selected from cell lysates (253).”